

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

Performance as at 30 November 2021¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	Since Inception (pa) ²
Total Return	-2.51	-0.30	-0.39	13.08	6.64	6.10	5.19	7.07
Income ³	0.00	0.00	6.07	9.97	5.15	6.02	6.01	6.52
Growth	-2.51	-0.30	-6.46	3.11	1.49	0.07	-0.82	0.55
Avg. Market Exposure ⁵	63%	62%	58%	56%	56%	58%	59%	59%


 $^{1\,}$ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions $2\,$ Inception date for performance calculation is $31\,$ December $2012\,$

Growth of \$10,000 Since Inception⁶



⁶ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance

Annual Distributions⁷



7 Illustrates Distribution Returns for the Talaria Global Equity Fund - Currency Hedged (Managed Fund) Units for the financial year ending 30 June 2021. Inception date is 31 December 2012.





³ Income includes realised capital gains 4 Past performance is not a reliable indicator of future performance

⁵ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio


Top 10 Holdings⁸

Company Name Holding Country Sector		Sector	Description			
Johnson & Johnson	5.9%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company		
Sanofi 4.4% France Healthcare		Healthcare	Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases			
McKesson	4.2%	USA	Healthcare	Largest pharmaceutical distributor in North America		
Sodexo	4.2%	France	Consumer Discretionary	A multinational food services and facilities management company		
Secom	4.1%	Japan	Industrials	Japan's largest protective and electronic security solutions provider		
Asahi Group	3.9%	Japan	Consumer Staples	Japan's largest brewer with increasing overseas market presence		
Omnicom	3.7%	USA	Communication Services	Global advertising and marketing services		
Mitsubishi Electric	3.6%	Japan	Industrials	One of Japan's largest industrial conglomerates		
Femsa	3.6%	Mexico	Consumer Staples	Mexican multinational beverage and retail company		
Swiss Re	3.5%	Switzerland	Financials	Global reinsurance company		

⁸ Weightings include option positions held and cash backing put options. It assumes that put options will be exercised.

Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation9



Regional Allocation¹⁰



9,10 Weightings include option positions held and cash backing put options It assumes that put options will be exercised.

Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options

Fund Snapshot

APIR Code	WFS0547AU	Inception Date	31 December 2012	
Management Fee	1.20% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily	
	Estimated to be 0.12% of net asset value	Exit Price	\$5.1849 (30 November 2021)	
Recoverable Expenses	of the Fund each Financial Year	Buy / Sell Spread	0.25% / 0.25%	
Major Platform	Asgard, Ausmaq, BT Wrap, BT Panorama, Hub24, IOOF, Linear, Macquarie, Netwealth, Powerwrap,	Distributions	Quarterly	
Availability	Praemium. Grow Wrap	Minimum Investment	\$5,000	

Important Information

